Cargando…

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease

BACKGROUND: Serum infliximab (IFX) and antibody-to-infliximab (ATI) levels are objective parameters, that may have a great role in the therapeutic decisions during maintenance biological therapy. RESEARCH DESIGN AND METHODS: 48 inflammatory bowel disease patients receiving maintenance IFX therapy we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bor, Renáta, Farkas, Klaudia, Fábián, Anna, Bálint, Anita, Milassin, Ágnes, Rutka, Mariann, Matuz, Mária, Nagy, Ferenc, Szepes, Zoltán, Molnár, Tamás
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376081/ https://www.ncbi.nlm.nih.gov/pubmed/28362851 http://dx.doi.org/10.1371/journal.pone.0172916

Ejemplares similares

Biological therapy and surgery rates in inflammatory bowel diseases – Data analysis of almost 1000 patients from a Hungarian tertiary IBD center
por: Szántó, Kata, et al.
Publicado: (2018)

The Use of Complementary and Alternative Medicine Is Less Frequent in Patients with Inflammatory Bowel Disease Than in Patients with Other Chronic Gastrointestinal Disorders
por: Fábián, Anna, et al.
Publicado: (2018)

Rectal Tumour Staging with Endorectal Ultrasound: Is There Any Difference between Western and Eastern European Countries?
por: Fábián, Anna, et al.
Publicado: (2016)

How disease extent can be included in the endoscopic activity index of ulcerative colitis: the panMayo score, a promising scoring system
por: Bálint, Anita, et al.
Publicado: (2018)

Diagnostic Accuracy of Five Different Fecal Markers for the Detection of Precancerous and Cancerous Lesions of the Colorectum
por: Rutka, Mariann, et al.
Publicado: (2016)

Endoscopic management of complications of self-expandable metal stents for treatment of malignant esophageal stenosis and tracheoesophageal fistulas
por: Bor, Renáta, et al.
Publicado: (2017)

Efficacy of the population-based pilot colorectal cancer screening, Csongrád county, Hungary, 2015
por: RUTKA, Mariann, et al.
Publicado: (2020)

Analysis of risk factors - especially different types of plexitis - for postoperative relapse in Crohn’s disease
por: Milassin, Ágnes, et al.
Publicado: (2017)

Comparison of therapeutic efficacy and treatment costs of self-expandable metal stents and plastic stents for management of malignant biliary obstruction
por: Bor, Renáta, et al.
Publicado: (2023)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Effect of COVID-19 pandemic on workflows and infection prevention strategies of endoscopy units in Hungary: a cross-sectional survey
por: Bor, Renáta, et al.
Publicado: (2021)

Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn’s disease: results from a multicentre cohort study
por: Bacsur, Péter, et al.
Publicado: (2022)

Prospective comparison of slow-pull and standard suction techniques of endoscopic ultrasound-guided fine needle aspiration in the diagnosis of solid pancreatic cancer
por: Bor, Renáta, et al.
Publicado: (2019)

Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients following COVID-19 vaccination
por: Resál, Tamás, et al.
Publicado: (2023)

Functional Anatomical Changes in Ulcerative Colitis Patients Determine Their Gut Microbiota Composition and Consequently the Possible Treatment Outcome
por: Bálint, Anita, et al.
Publicado: (2020)

The complex relationship between viruses and inflammatory bowel disease – review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic
por: Farkas, Klaudia, et al.
Publicado: (2021)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Effects of bowel cleansing on the composition of the gut microbiota in inflammatory bowel disease patients and healthy controls
por: Bacsur, Péter, et al.
Publicado: (2023)

Risk Factors and Interpretation of Inconclusive Endoscopic Ultrasound-Guided Fine Needle Aspiration Cytology in the Diagnosis of Solid Pancreatic Lesions
por: Bor, Renáta, et al.
Publicado: (2023)

Specific T-Cell Subsets Can Predict the Efficacy of Anti-TNF Treatment in Inflammatory Bowel Diseases
por: Dulic, Sonja, et al.
Publicado: (2020)

Conception and reality: Outcome of SARS-CoV-2 infection and vaccination among Hungarian IBD patients on biologic treatments
por: Resál, Tamás, et al.
Publicado: (2022)

Infliximab in inflammatory bowel disease
por: Papamichael, Konstantinos, et al.
Publicado: (2019)

Effect of COVID-19 pandemic on the workflow of endoscopy units: an international survey
por: Resál, Tamás, et al.
Publicado: (2021)

Still the Joker in the Pack: When to Take Out Cyclosporine in the Game?
por: Resál, Tamás, et al.
Publicado: (2021)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease
por: Gomes, Luis Eduardo Miani, et al.
Publicado: (2019)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
por: Peng, Kuan, et al.
Publicado: (2023)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
por: Jukic, Tomislav, et al.
Publicado: (2023)

Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary – a population-based study
por: Kunovszki, Péter, et al.
Publicado: (2020)

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
por: Vande Casteele, Niels, et al.
Publicado: (2015)

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe - a Hungarian nationwide observational study
por: Miheller, Pál, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_jrhucb3nti3a2ur83lma5hhi0r